secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0000879169-24-000074
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M
--------------------------------------------------------------------------------

- Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.
- Jakafi net revenues $572M (-1% YoY) despite 5% paid patient growth; inventory drawdown of ~$55M.
- Opzelura revenues $86M (+52% YoY) driven by AD and vitiligo uptake.
- Incyte to acquire Escient Pharmaceuticals for $750M plus net cash; lead candidate EP262 for CSU.
- FY2024 guidance reaffirmed: Jakafi $2.69-2.75B; R&D $1.72-1.76B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/0000879169-24-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916924000074/incy-20240430.htm
  HTML page:      https://secwatch.observer/filing/0000879169-24-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer